University of Paris-Saclay, Inserm, CESP, Team MOODS, 94270, Le Kremlin-Bicêtre, France.
Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital, Department of Psychiatry, 94270, Le Kremlin-Bicêtre, France.
BMC Geriatr. 2022 Jan 3;22(1):4. doi: 10.1186/s12877-021-02726-5.
Road safety is a major issue among seniors. Potentially Driver-Impairing (PDI) drugs are known to increase the risk of car accident. The aim of this cross-sectional study was to describe PDI-drug consumption among older drivers and determine associated factors.
The S.AGES cohort is a French non-interventional real-life prospective study of 3700 community-dwelling participants aged ≥65 years old, suffering from type 2 diabetes (T2DM), chronic pain or atrial fibrillation (AF). Baseline data of drivers with known treatment (n = 1783) were used for the analyses. PDI drugs were defined according to the French classification.
One thousand seven hundred eighty-three drivers were included (66% males; mean age 76 (Standard deviation = 5.78) years old). 21% (n = 373) took PDI drugs, 64% of which took only one (n = 239). The most frequent PDI drugs were: Zolpidem (11%; n = 60); Zopiclone (8%; n = 45); Bromazepam (8%; n = 44); Tramadol (7%; n = 39); Pregabalin (6%; n = 31). Drivers taking PDI drugs had more often chronic pain (OR [95% CI] = 2.30 [1.54-3.46]), history of depressive disorder (4.28 [3.00-6.14]) and polypharmacy (taking at least 5 different medications; 4.32 [2.97-6.41]), and less often T2DM (0.54 [0.37-0.79]), and AF (0.48 [0.32-0.71]). Conversely, they had a lower Activities of Daily Living score (0.34 [0.17-0.68]).
The rate of aged drivers in the S.AGES cohort taking PDI drugs is concerning and highlights the need to carefully assess and reassess PDI-drug prescriptions in this population, particularly hypnotics, anxiolytics and opioids.
ClinicalTrials.gov NCT01065909 (First posted: February 9th, 2010).
道路安全是老年人面临的主要问题之一。已知潜在的致驾驶员损害（PDI）药物会增加车祸风险。本横断面研究的目的是描述老年驾驶员中 PDI 药物的使用情况，并确定相关因素。
S.AGES 队列是一项法国非干预性真实前瞻性研究，纳入了 3700 名年龄≥65 岁、患有 2 型糖尿病（T2DM）、慢性疼痛或心房颤动（AF）的社区居民。对已知治疗方案的驾驶员（n=1783）的基线数据进行了分析。PDI 药物根据法国分类进行定义。
纳入了 1783 名驾驶员（66%为男性；平均年龄 76（标准差=5.78）岁）。21%（n=373）服用了 PDI 药物，其中 64%（n=239）仅服用一种 PDI 药物。最常见的 PDI 药物是：唑吡坦（11%；n=60）；佐匹克隆（8%；n=45）；溴马唑仑（8%；n=44）；曲马多（7%；n=39）；普瑞巴林（6%；n=31）。服用 PDI 药物的驾驶员更常患有慢性疼痛（OR[95%CI] = 2.30[1.54-3.46]）、抑郁障碍病史（4.28[3.00-6.14]）和多药治疗（至少服用 5 种不同的药物；4.32[2.97-6.41]），而 T2DM（0.54[0.37-0.79]）和 AF（0.48[0.32-0.71]）的患病率较低。相反，他们的日常生活活动评分较低（0.34[0.17-0.68]）。
S.AGES 队列中服用 PDI 药物的老年驾驶员比例令人担忧，这凸显了需要仔细评估和重新评估该人群中 PDI 药物的处方，特别是催眠药、抗焦虑药和阿片类药物。
ClinicalTrials.gov NCT01065909（首次发布日期：2010 年 2 月 9 日）。
